Keyphrases
Early Signs
100%
Follicular Lymphoma
100%
Immunogenic
100%
Human Immune System
100%
Programmed Death-ligand 1 (PD-L1)
100%
First-in-human
100%
L1-L2
100%
PD-L2
100%
Immune Modulatory Vaccine
100%
Peripheral Blood Mononuclear Cells
28%
Pseudoprogression
28%
Clinical Efficacy
14%
Injection Site Reaction
14%
Complete Remission
14%
Vaccination
14%
Cytotoxicity
14%
Specific T Cells
14%
Regulatory Function
14%
Conventional Chemotherapy
14%
Lymphoma Patients
14%
Neutropenia
14%
Tumor Microenvironment
14%
Regulatory T Cells
14%
Long-term Disease
14%
Thrombocytopenia
14%
ELISPOT
14%
Specific Immune Response
14%
Flu-like
14%
Checkpoint Molecules
14%
Anti-tumor Immune
14%
Tumor Immune Activity
14%
Grade 12
14%
Immune Composition
14%
Disease Regression
14%
Epitope Vaccine
14%
Pharmacology, Toxicology and Pharmaceutical Science
Follicular Lymphoma
100%
Remission
66%
Neoplasm
33%
Vaccination Policy
33%
Injection Site Reaction
33%
Chemotherapy
33%
Cytotoxicity
33%
Thrombocytopenia
33%
Epitope
33%
Neutropenia
33%
Flu Like Syndrome
33%
Tumor Microenvironment
33%
Programmed Death 1 Ligand 1
33%
Programmed Death 1 Ligand 2
33%
Immunology and Microbiology
Vaccine Efficacy
100%
Programmed Death-Ligand 1
100%
Peripheral Blood Mononuclear Cell
33%
Immune Response
16%
T Cell
16%
Vaccination Policy
16%
Epitope
16%
Cytotoxicity
16%
Regulatory T Cell
16%
Influenza
16%
Programmed Death 1 Ligand 1
16%
Programmed Death 1 Ligand 2
16%
Biochemistry, Genetics and Molecular Biology
PD-L1
100%
Peripheral Blood Mononuclear Cell
33%
Enzyme
16%
Thrombocytopenia
16%
T Cell
16%
Cytotoxicity
16%
Regulatory T Cell
16%
Immune Response
16%